StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

Research analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Tuesday. The firm set a “hold” rating on the stock.

Several other equities research analysts have also commented on the company. Lake Street Capital reduced their price objective on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Ekso Bionics in a research note on Tuesday, March 4th.

Ekso Bionics Price Performance

Shares of EKSO opened at $0.40 on Tuesday. The firm has a market cap of $10.04 million, a PE ratio of -0.62 and a beta of 1.43. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The firm has a fifty day simple moving average of $0.59 and a two-hundred day simple moving average of $0.80. Ekso Bionics has a 1-year low of $0.34 and a 1-year high of $1.53.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The company had revenue of $5.09 million for the quarter, compared to analysts’ expectations of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. On average, equities analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.